Exemestane vs Liothyronine (T3)
FDA Approved vs FDA Approved
compatible Mechanism-based · 45% Both Exemestane and Liothyronine (T3) enhance protein synthesis. Generally compatible — may provide additive anabolic benefits for muscle growth and recovery.
Molecular Data
Exemestane Liothyronine (T3)
Weight 296.40 Da 650.97 Da
Half-life ~24 hours ~1 day
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Thyroid hormone (C15H12I3NO4)
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Liothyronine (T3)
01 Direct and rapid increase in basal metabolic rate
02 Enhanced fat oxidation and lipolysis
03 Improved energy levels and reduction of hypothyroid fatigue
04 Faster-acting than T4 with effects noticeable within hours to days
05 Useful when peripheral T4-to-T3 conversion is impaired (illness, caloric deficit, stress)
06 Supports body temperature regulation and thermogenesis
07 Can improve cognitive clarity and reduce brain fog associated with low thyroid function
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Liothyronine (T3)
Tachycardia and palpitations (increased heart rate, especially at higher doses)
Anxiety, nervousness, and irritability
Insomnia and disrupted sleep architecture
Increased sweating and heat intolerance
Tremor (fine hand tremor, similar to hyperthyroid presentation)
Increased appetite despite accelerated metabolism
Loose stools or increased bowel frequency
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Untreated adrenal insufficiency (must correct cortisol deficiency before starting T3)
Acute myocardial infarction or unstable angina
Thyrotoxicosis or untreated hyperthyroidism
Known hypersensitivity to liothyronine or any tablet excipients
Uncorrected adrenal cortical insufficiency (risk of adrenal crisis)
Research Evidence
Exemestane Liothyronine (T3)
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest — September 2023
FDA Approved Yes Yes
Full Exemestane profile Full Liothyronine (T3) profile Exemestane calculator Liothyronine (T3) calculator
More comparisons: Testosterone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.